• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter recalls some syringe pumps due to underdosing risk

November 16, 2023 By Sean Whooley

Baxter Novum IQ Infusion
[Image from Baxter website]
The FDA determined that the recall of the Baxter (NYSE:BAX) Novum IQ syringe pump is Class 1, the most serious kind.

Baxter designed its Novum IQ syringe pump as an infusion pump to deliver fluids into a patient’s body in a controlled manner. The device is suitable for patient care in hospitals and outpatient facilities for adults, pediatrics and neonates. The FDA cleared the Novum IQ infusion pump with Dose IQ safety software in August 2022.

Deerfield, Illinois-based Baxter recalled the pump because it may incorrectly indicate the completion of an infusion. The company traced the issue to a software error that may miscalculate volume after the pump detects an occlusion. Use of the pump could lead to serious adverse health consequences and death. It could lead to the failure to receive the amount of fluids they need or the delay of time-sensitive treatment.

Underdosing or delays can especially lead to consequences for people receiving life-sustaining medications. Baxter reports no serious injuries or death associated with the issue to date, though.

The company recalled 2,023 devices in the U.S., distributed between March 10, 2023, and Aug. 16, 2023. It initiated the recall on Sept. 21, 2023.

Baxter instructed affected customers to monitor the remaining fluid in the syringe after completing an infusion, especially when one or multiple downstream occlusions alarm. If the total dose isn’t delivered upon the “Infusion Complete” alarm, users should reprogram the pump and deliver the remaining volume as necessary.

Company representatives intend to contact affected facilities once the software upgrade becomes available.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Technology Tagged With: Baxter, FDA

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS